ClinicalTrials.gg
RecruitingNCT06467526Updated Oct 22, 2026

Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss

A Phase 2 interventional study of Hydroxychloroquine and Steroid in Sudden Hearing Loss, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 22, 2026Now RecruitingFirst site in Taiwan+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours. In clinical settings, steroids are the predominant treatment for SSNHL. However, the outcomes for patients undergoing steroid therapy for SSNHL can differ substantially. Moreover, a systematic review of randomized clinical trials has found no conclusive evidence pinpointing an effective treatment for SSNHL. Hydroxychloroquine, a derivative of chloroquine, is a medication that has gained attention for its potential role in modulating the immune response. We aim to see if hydroxychloroquine could augment hearing recovery in SSNHL under steroid treatment and to evaluate the safety of hydroxychloroquine in the treatment of SSNHL patients. We plan to enroll 80 SSNHL patients who received oral steroid therapy and randomize them into an experimental group (hydroxychloroquine with prednisolone, 40 patients) and a control group (prednisolone, 40 patients). The primary endpoint will be the change in pure tone audiogram (PTA) in the affected ear from screening until 3 months. The secondary endpoints will be the change in word recognition score and the change in bilateral tinnitus severity after treatment. Any side effects will be recorded to ensure the safety of this clinical trial.

Read the detailed description

Sudden sensorineural hearing loss (SSNHL) significantly affects a patient's social and interpersonal interactions. It presents as an abrupt decrease in hearing, usually within a matter of hours or days. SSNHL typically impacts one ear and can range in severity, sometimes resulting in total deafness. In clinical settings, steroids are the predominant treatment for SSNHL. Yet, the outcomes for patients undergoing steroid therapy for SSNHL can differ substantially. Hydroxychloroquine, a derivative of chloroquine, is a medication that has gained attention for its potential role in modulating the immune response. Our study hypothesized that hydroxychloroquine could help the hearing recovery during the steroid treatment for SSNHL.

In this project, we will enroll two groups of subjects for our study.

  1. Experimental group: Treatment with oral prednisolone (5 mg) for 14 days (high dosage 1 mg/kg/day for 7 days and gradually taper in the next week) and hydroxychloroquine for 60 days (400 mg/day)
  2. Control group: Treatment with oral prednisolone (5 mg) for 14 days (high dosage 1 mg/kg/day for 7 days and gradually taper in the next week)

A. Primary endpoint:

The primary outcome measure for this study is the change in pure tone audiogram (PTA) in the affected ear from screening until 3 months. The PTA will be calculated as the arithmetic mean of air conduction thresholds at the frequency of 0.5k, 1k, 2k, and 4 kHz.

B. Secondary endpoints:

  1. the change in PTA in the bilateral ear from screening until one week, two weeks, one month, and two months
  2. change in word recognition score (WRS) in the bilateral ear from screening to one week, two weeks, one month, two months and three months
  3. The grade of hearing recovery by Siegel's criteria from screening to 3 months
  4. Percentage of recovery from screening until 3 months
  5. change in bilateral tinnitus severity (evaluted by VAS and THI) from screening to one month, 2 months and 3 months
02

Conditions studied

  • Sudden Hearing Loss

Browse trials for

03

In context

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

This study's planned enrollment of 80 is above the median of 72 across 49 interventional studies indexed under Hearing Loss, Sudden.

Browse Hearing Loss, Sudden studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unilateral idiopathic sudden sensorineural hearing loss ≥ 30 dB in at least 3 consecutive frequencies, compared to the contralateral ear, within 3 days
  2. Enrollment has to be accomplished within 14 days after SSNHL onset
  3. Male or female aged ≥ 18 to 70 years
  4. Ability to understand and follow the study protocol

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breast-feeding female
  2. positive pregnancy test before receiving the study drug
  3. Due to a history of physical efforts suspected perilymph fistula or membrane rupture.
  4. Previously existing, known retrocochlear hearing loss
  5. Any history of any ear operation or chronic inflammatory disease of middle ear in the past one year
  6. History of blunt or penetrating ear trauma, head trauma, barotrauma, or acoustic trauma immediately preceding SSHL.
  7. History of Meniere's disease, hearing loss, radiation-induced hearing loss, endolymphatic hydrops, and otosclerosis.
  8. History of chronic inflammatory diseases or autoimmune diseases
  9. Prior chemotherapy or treatment with drugs
  10. Patients on renal dialysis
  11. Patients with history of retinopathy, or are using drugs that could induce retinopathy, such as Tamoxifen
  12. History of allergy to hydroxychloroquine
  13. Patients who are with oral treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Hydroxychloroquine group

    Hydroxychloroquine with steroid

    Drug: Hydroxychloroquine · Drug: Steroid

  • Other
    Control group

    Steroid only

    Drug: Steroid

Interventions

  • Oral hydroxychloroquine (400mg/day) for 2 months

  • DrugSteroidsStudies of SteroidsSteroids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)

06

What researchers measure

Primary outcomes

  1. Hearing improvement

    To evaluate if hydroxychloroquine could increase the hearing improvement

    Time frame: from screening until 3 months

Secondary outcomes

  1. Word recognition score

    To evaluate if hydroxychloroquine could increase the word recognition score

    Time frame: from screening until 3 months

  2. Tinnitus severity

    To evaluate if hydroxychloroquine could decrease the tinnitus severity

    Time frame: from screening until 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Jul 2024 → Sep 2024 and primary completion May 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2024
First posted
Jun 21, 2024
StartActual
Sep 10, 2024was Jul 2024
Primary completionEst.
Dec 31, 2026was May 2026
CompletionEst.
Mar 31, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
1 site added — first site in Taiwan
Show site
  • Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwan
Oct 22, 2026
Start date
Jul 1, 2024→Sep 10, 2024 (actual)
Oct 22, 2026
Primary completion
May 31, 2026→Dec 31, 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Taiwan
    Show site
    • Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwan
    Start date Jul 1, 2024→Sep 10, 2024 (now actual)
    Primary completion May 31, 2026→Dec 31, 2026
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06467526
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Sep 10, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Chao-Hui Yang, MD,PhD
Contact
chouwhay@gmail.com
88677317123 ext. 2531
Chao-Hui Yang
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxychloroquine

Start the discussion